Deoxyribonucleic acid (DNA) nucleophilic sites (DNA)

DNA guanine and other nucleophilic sites within the genome represent the fundamental molecular targets for alkylating agents and platinum-based antineoplastic drugs. These chemical species possess electrophilic properties that allow them to form strong covalent bonds with electron-rich atoms in DNA, most notably the N7 nitrogen atom of guanine (StatPearls: Alkylating Agents, 2023). This interaction results in the formation of DNA adducts, which can lead to intra-strand or inter-strand cross-linking, effectively tethering the two strands of the double helix together or distorting its structure. Such modifications physically impede the progression of DNA polymerase and RNA polymerase, thereby halting DNA replication and gene transcription (NIH: DNA Damage and Repair). The resulting genomic instability and persistent DNA damage activate apoptotic signaling pathways, leading to the death of the affected cell. While highly effective against rapidly proliferating malignant cells, these interactions are not site-specific, often leading to collateral damage in healthy tissues and potential long-term risks such as secondary leukemias (PubChem: Cisplatin).

Other names

DNA guanineGuanine N7Nucleophilic DNA basesGenomic DNADNA adduct sites

Drugs targeting these sites act by forming covalent adducts with DNA bases, primarily guanine at the N7 position. This process, known as alkylation or platination, creates physical barriers (cross-links) that prevent DNA strand separation. Consequently, DNA replication and transcription are inhibited, triggering the DNA damage response and leading to cell cycle arrest or apoptosis (StatPearls: Alkylating Agents, 2023; NIH: DNA Damage and Repair).